Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Reversible siRNA-based silencing of mutant and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease

Reversible siRNA-based silencing of mutant and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease

US Patent 8217018 · Granted Jul 10, 2012

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Alzheimer's disease animal model2021
Alzheimer's disease animal model2018
Vector for the selective silencing of a gene in astrocytes2017
Use of IL-6/IL-6 chimera in Huntington's disease2012
Hypoxia responsive EPO producing cells1999